Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: pathogenesis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Korfei, U. Tenekeci, O. Klymenko, C. Ruppert, W. Klepetko, L. Fink, W. Seeger, A. Guenther (Giessen, Greifenstein, Germany; Vienna, Austria). Regulation and localization of the telomerase enzyme-complex and the shelterin-telosom-complex in sporadic idiopathic pulmonary fibrosis (IPF). Eur Respir J 2013; 42: Suppl. 57, 3526

Member's Comments

No comment yet.

Related content which might interest you: Loss of PTEN induced lung fibroblasts exhibiting similar pathogenic features to cancer cells in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Inhibition of profibrotic signaling in fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) by histone deacetylase-inhibitors (HDACi) or the IPF drug pirfenidone Source: International Congress 2014 – ILDs 1 Year: 2014 Distinct gene expression profiles of cultured stromal cells from the patients with idiopathic pulmonary fibrosis and lung adenocarcinoma Source: International Congress 2015 – Translational studies in airway cell biology Year: 2015 Club cell secretory protein-CC16 is increased in idiopathic pulmonary fibrosis Source: International Congress 2016 – ILD pathogenesis Year: 2016 Comparative proteome analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF) and non-specific interstitial pneumonia (NSIP) Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Role of Bcl-xL in hepatocyte growth factor elicited epithelial protection in idiopathic lung fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: pathogenesis Year: 2013 Does apoptosis evasion only affect fibroblasts from idiopathic pulmonary fibrosis? Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013 Effect of pirfenidone on TGF-beta-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Nintedanib prevents IL-1beta-stimulated proliferation of primary human lung fibroblasts from patients with idiopathic pulmonary fibrosis or from control donors Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Role of MUC1 in idiopathic pulmonary fibrosis Source: International Congress 2016 – ILD pathogenesis Year: 2016 Circulating monocytes from interstitial lung disease patients show an activated phenotype Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Dasatinib suppresses TGFbeta-induced epithelial mesenchymal transition and inhibits pulmonary fibrosis Source: International Congress 2014 – ILDs 1 Year: 2014 Change of A549 cells characteristics upon stimulation with BALF of patients with interstitial lung diseases Source: International Congress 2014 – ILDs 4 Year: 2014 The ratio AGE/RAGE is increased in idiopathic pulmonary fibrosis Source: International Congress 2015 – Connective tissue disorders Year: 2015 Epithelial mesenchymal transition in fibroblastic foci of different fibrosing lung diseases: Repair or remodeling? Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: pathogenesis Year: 2013 Neoplasia in patients with ILD; shortened survival Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Interstitial lung disease in elderly subjects Source: Eur Respir Mon; 2009: 43: 150–162 Year: 2009 Anti-parietal cell autoimmunity in IPF patients Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Prognostic influence of comorbidities in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 2 Year: 2014 Comparison of physiological impairment in ILD patients with and without diagnostic IPF features Source: International Congress 2014 – ILDs 4 Year: 2014